製药和生物技术分销贸易：2020-2025

《製药和生物技术领域的分销交易》深入理解和分析了公司如何以及为何达成分销交易。本报告提供了2020年至2025年零售贸易的详细资讯。

此报告提供双方宣布的分销交易的付款条款。这些数据为付款条款和其他贸易条款提供了宝贵的见解。

了解潜在合作伙伴谈判交易条款的弹性可以为谈判过程提供重要的见解，让您了解谈判条款时会发生什么。许多中小企业可能会要求详细的付款条款，但当涉及如何触发付款和权利转移时，细节决定成败。这种见解在新闻稿或资料库中找不到，而是来自合约文件。

本报告提供了自 2020 年以来宣布的分销交易的综合列表，这些交易记录在“当前协议”交易和合作伙伴关係数据库中，包括可用的财务条款，以及公司及其合作伙伴向 SEC 提交的实际分销交易文件的在线副本链接。

报告的第一部分涵盖贸易和商业活动。

第 1 章对报告进行了介绍，第 2 章概述并分析了分销趋势，并讨论了交易类型的好处。

第 3 章概述了分销协议的结构。

第 4 章回顾了 2020 年及以后的主要经销项目。交易按标题价值列出。对于与美国证券交易委员会 (SEC) 公开宣布的协议交易，可以透过目前协议交易和联盟资料库中的连结在线存取。

第 5 章提供了最活跃的 25 家经销商和贸易商的综合清单。每个交易标题都透过当前协议的交易和联盟资料库连结到完整交易记录的线上版本，并在可用时连结到实际合约文件，从而可以轻鬆按需存取每个交易记录。

第 6 章对 2020 年以来达成或宣布的分销交易进行了全面深入的回顾，按公司 A-Z、治疗方式、技术和行业垂直分类，并提供合约文件。合约文件详细介绍了双方就分销交易达成的实际条款和条件。

交易目录包含自 2020 年以来宣布的所有分销交易的综合清单。每个清单都按公司 A-Z、治疗领域和技术类型组织成交易目录。每个交易标题透过超连结连结到交易记录的线上版本，包括实际的合约文件。

该报告还包含大量图表和图形，展示了 2020 年及以后的交易趋势和活动。

目录

摘要整理

第1章 -简介

第2章 流通交易趋势

• 简介
• 流通交易定义
• 2020年以后的流通交易趋势
  • 流通交易的各年度转变，2020年～2025年
  • 各开发阶段的流通交易，2020年～2025年
  • 产业各部门的流通交易，2020年～2025年
  • 各治疗领域的流通交易，2020年～2025年，
  • 各技术类型的流通交易，2020年～2025年
  • 最活跃的各企业的流通交易，2020年～2025年
  • 纯粹的流通交易的属性
  • 复数零组件交易能放的流通的属性
• 调整合作伙伴使之有作用流通交易

第3章 流通交易结构概要

• 简介
• 销售契约结构
• 更广泛的联盟契约的一环的发行权

第4章 -主要流通交易

• 简介
• 主要的流通交易，各金额

第5章 -最活跃的 25 位经销商

• 简介
• 最活跃的流通交易业者主要25公司

包含第6章 -契约名录的流通交易

• 简介
• 按契约流通交易，2020年～2025年
• 交易名录
• 交易名录- 各企业流通交易一览(AZ)
• 交易名录- 各治疗领域的流通交易
• 交易名录- 各技术类型的流通交易
• 关于调查公司
• 目前联盟
• 目前契约
• Current Partnering的最近的报告标题

Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals.

Fully revised and updated, the report provides details of distribution deals from 2020 to 2025.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The deal directory includes a comprehensive listing of all distribution deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2020.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Key benefits

Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse distribution deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Distribution Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Deals in Pharmaceuticals and Biotechnology includes:

• Trends in distribution dealmaking in the biopharma industry
• Overview of distribution deal structure
• Directory of distribution deal records covering pharmaceutical and biotechnology
• The leading distribution deals by value
• Most active distribution dealmakers
• The leading distribution partnering resources

In Distribution Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Distribution Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for distribution deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

• 2.1. Introduction
• 2.2. Definition of distribution deals
• 2.3. Trends in distribution deals since 2020
  • 2.3.1. Distribution dealmaking by year, 2020-2025
  • 2.3.2. Distribution dealmaking by phase of development, 2020-2025
  • 2.3.3. Distribution dealmaking by industry sector, 2020-2025
  • 2.3.4. Distribution dealmaking by therapy area, 2020-2025
  • 2.3.5. Distribution dealmaking by technology type, 2020-2025
  • 2.3.6. Distribution dealmaking by most active company, 2020-2025
  • 2.3.7. Attributes of pure distribution deals
  • 2.3.8. Attributes of distribution in multi-component deals
• 2.4. Aligning partners to make the distribution agreement work

Chapter 3 - Overview of distribution deal structure

• 3.1. Introduction
• 3.2. Distribution agreement structure
• 3.3. Distribution rights as part of a wider alliance agreement

Chapter 4 - Leading distribution deals

• 4.1. Introduction
• 4.2. Top distribution deals by value

Chapter 5 - Top 25 most active distribution dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active distribution dealmakers

Chapter 6 - Distribution deals including contracts directory

• 6.1. Introduction
• 6.2. Distribution deals with contracts 2020-2025
• Deal directory
• Deal directory - distribution dealmaking by companies A-Z
• Deal directory - distribution dealmaking by therapy area
• Deal directory - distribution dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of distribution
• Figure 2: Trends in distribution deal announcements, 2020-2025
• Figure 3: Distribution deals signed at each phase of development, 2020-2025
• Figure 4: Distribution deals by industry sector, 2020-2025
• Figure 5: Distribution deals by therapy area, 2020-2025
• Figure 6: Distribution deals by technology type, 2020-2025
• Figure 7: Top 25 most active distribution dealmakers, 2020-2025
• Figure 8: Issues in implementing distribution agreements
• Figure 9: Distribution agreements - what should a contract include?
• Figure 10: Components of the distribution deal structure
• Figure 11: Top distribution deals by value 2020-2025
• Figure 12: Most active distribution dealmakers 2020-2025